Dr. Igor Gonda, Ph.D. is the President, Chief Executive Officer, Director of Aradigm Corporationration He has served as the company President and Chief Executive Officer since August 2006 and as a director since September 2001. From December 2001 to August 2006, Dr. Gonda was the Chief Executive Officer and Managing Director of Acrux Limited, a publicly traded specialty pharmaceutical company located in Melbourne, Australia. From July 2001 to December 2001, Dr. Gonda was the company Chief Scientific Officer and, from October 1995 to July 2001, was the company Vice President, Research and Development. From February 1992 to September 1995, Dr. Gonda was a Senior Scientist and Group Leader at Genentech, Inc. His key responsibilities at Genentech were the development of the inhalation delivery of rhDNase for the treatment of cystic fibrosis and nonparenteral methods of delivery of biologics. Prior to that, Dr. Gonda held academic positions at the University of Aston in Birmingham, United Kingdom, and the University of Sydney, Australia. Dr. Gonda holds a B.Sc. in Chemistry and a Ph.D. in Physical Chemistry from Leeds University, United Kingdom. Dr. Gonda was the Chairman of the company Scientific Advisory Board until August 2006.
President CEO, Director
Age: 63 CEO Since 2006
The company has return on total asset (ROA) of (69.42) % which means that it has lost $69.42 on every $100 spent on asset. This is way below average.
The company has accumulated 8.27 M in total debt. Aradigm Corporation has Current Ratio of 7.34 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.
Entity SummaryAradigm Corporationration, a specialty pharmaceutical company, engages in the development and commercialization of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. Aradigm Corporation [ARDM] is traded as part of a regulated electronic trading service offered by the NASD. Filter other
|Click to run this filter|| |
Filter Other Insiders
| ARDM OTC BB
Aradigm Corporation has more than 97.0 (%) percent chance of experiencing financial distress in the next 2 years of operations.
Aradigm price boundaries
Promote Aradigm and Igor Gonda